Title: New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Journal: BJU international 20120801
Title: Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Journal: International journal of urology : official journal of the Japanese Urological Association 20120701
Title: Androgen deprivation therapy: past, present and future.
Journal: BJU international 20120601
Title: New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Journal: BJU international 20120301
Title: Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists.
Journal: Current opinion in obstetrics & gynecology 20110801
Title: An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.
Journal: Therapeutic advances in urology 20110601
Title: Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.
Journal: OncoTargets and therapy 20110101
Title: Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.
Journal: PloS one 20110101
Title: Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples.
Journal: British journal of clinical pharmacology 20101001
Title: GnRH antagonists in the treatment of advanced prostate cancer.
Journal: The Canadian journal of urology 20100401
Title: Retraction statement: Reconstitution of Plenaxis® (Abarelix) 100 mg for injection is more effective with a vortex-like mixer than when performed manually.
Journal: Journal of pharmacy practice 20100201
Title: Evaluation of degarelix in the management of prostate cancer.
Journal: Cancer management and research 20100101
Title: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
Journal: BJU international 20091201
Title: [GnRH antagonists--a new therapy option for advanced prostate cancer].
Journal: Aktuelle Urologie 20090501
Title: Will GnRH antagonists improve prostate cancer treatment?
Journal: Trends in endocrinology and metabolism: TEM 20090101
Title: Degarelix and its therapeutic potential in the treatment of prostate cancer.
Journal: Clinical interventions in aging 20090101
Title: Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
Journal: Clinical interventions in aging 20090101
Title: Leuprorelin depot injection: patient considerations in the management of prostatic cancer.
Journal: Therapeutics and clinical risk management 20080401
Title: Distinguishing compounds with anticancer activity by ANN using inductive QSAR descriptors.
Journal: Bioinformation 20080101
Title: Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902.
Journal: Endocrinology 20070201
Title: Hormone ablation therapy: lightening the load for today's prostate cancer patient.
Journal: Urologic nursing 20070201
Title: Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
Journal: Future oncology (London, England) 20061201
Title: Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
Journal: Anti-cancer drugs 20061001
Title: Proprietary Rel-Ease drug delivery technology: opportunity for sustained delivery of peptides, proteins and small molecules.
Journal: Expert opinion on drug delivery 20060901
Title: The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
Journal: The Journal of urology 20060801
Title: Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Journal: International journal of urology : official journal of the Japanese Urological Association 20060301
Title: Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Journal: International journal of urology : official journal of the Japanese Urological Association 20060101
Title: [GnRH antagonists: present and future].
Journal: Annales d'urologie 20051001
Title: Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.
Journal: Urology 20050401
Title: Innovations in antineoplastic therapy.
Journal: The Nursing clinics of North America 20050301
Title: Abarelix (plenaxis).
Journal: Clinical journal of oncology nursing 20041201
Title: Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer.
Journal: Expert opinion on pharmacotherapy 20041001
Title: Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
Journal: European urology 20040901
Title: Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
Journal: Journal of clinical pharmacology 20040501
Title: Abarelix (Plenaxis) for advanced prostate cancer.
Journal: The Medical letter on drugs and therapeutics 20040315
Title: Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer.
Journal: Clinical prostate cancer 20040301
Title: Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
Journal: Urology 20040201
Title: Plenaxis.
Journal: Discovery medicine 20040201
Title: New treatment for advanced prostate cancer.
Journal: FDA consumer 20040101
Title: Gonadotropin-releasing hormone antagonist in the management of prostate cancer.
Journal: Reviews in urology 20040101
Title: Experimental use of GnRH antagonists as second-line hormonal therapy.
Journal: Reviews in urology 20040101
Title: Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
Journal: Urology 20031222
Title: An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists.
Journal: Urology 20031101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20031101
Title: Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
Journal: The Journal of urology 20030501
Title: Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer.
Journal: Clinical pharmacology and therapeutics 20030401
Title: Encouraging results for Plenaxis in prostate cancer trial.
Journal: Expert review of anticancer therapy 20030401
Title: Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827.
Journal: Drugs in R&D 20030101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20021101
Title: Hormonal therapy of prostate cancer.
Journal: Seminars in urologic oncology 20020801
Title: Gateways to Clinical Trials. June 2002.
Journal: Methods and findings in experimental and clinical pharmacology 20020601
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20020501
Title: Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
Journal: The Journal of pharmacology and experimental therapeutics 20020401
Title: A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.
Journal: The Journal of urology 20020401
Title: New single-isomer compounds on the horizon.
Journal: CNS spectrums 20020401
Title: A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
Journal: Urology 20011101
Title: Luteinizing hormone-releasing hormone antagonists in prostate cancer.
Journal: Urology 20010801
Title: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Journal: The Journal of urology 20010501
Title: GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.
Journal: Journal of medicinal chemistry 20010201
Title: Androgen deprivation and other treatments for advanced prostate cancer.
Journal: Reviews in urology 20010101
Title: The evolution of hormonal therapy for prostatic carcinoma.
Journal: Reviews in urology 20010101
Title: Emerging pharmacologic therapies for prostate cancer.
Journal: Reviews in urology 20010101
Title: Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010 Oct;70(4):580-7.
Title: Kirby RS, et al. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4.
Title: Debruyne F, et al. Abarelix for injectable suspension: first-in-class releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2(6):677-96.
